Toxicidades cutáneomucosas secundarias a terapias dirigidas e inmunoterapia
eBook - ePub

Toxicidades cutáneomucosas secundarias a terapias dirigidas e inmunoterapia

  1. 112 pages
  2. English
  3. ePUB (mobile friendly)
  4. Available on iOS & Android
eBook - ePub

Toxicidades cutáneomucosas secundarias a terapias dirigidas e inmunoterapia

About this book

El advenimiento de las terapias moleculares dirigidas y de la inmunoterapia en la última década representa sin duda un gran adelanto en la medicina. Este cambio de paradigma promete muchísimos avances en el campo de la medicina individualizada.A pesar de que estos fármacos suelen tener un mejor perfil de seguridad que los quimioterápicos convencionales, no se encuentran exentos de efectos adversos; y uno de los órganos más afectados es la piel.Sin embargo, es frecuente que estas toxicidades cutáneomucosas sean subdiagnosticadas– probablemente por su desconocimiento– y la demora que se produce en su diagnóstico puede afectar seriamente la calidad de vida del paciente y la regularidad del curso del tratamiento oncológico.Esto hace que la participación interdisciplinaria entre oncólogos y dermatólogos sea esencial para el paciente. La piedra angular del manejo de estos pacientes debe ser la educación y el acompañamiento terapéutico para lograr realizar un diagnóstico y tratamiento tempranos del amplio espectro de efectos adversos mucocutáneos secundarios a las nuevas terapias emergentes. De esta forma, nuestro objetivo es mejorar en conjunto el campo de la oncodermatopatología.

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Toxicidades cutáneomucosas secundarias a terapias dirigidas e inmunoterapia by Camila Delgadillo Jordán,Corina Busso in PDF and/or ePUB format, as well as other popular books in Medicine & Toxicology. We have over one million books available in our catalogue for you to explore.

Information

Publisher
Editora Dialética
Year
2024
eBook ISBN
9786527038160
Topic
Medicine
Subtopic
Toxicology

Table of contents

  1. Capa
  2. Folha de Rosto
  3. Créditos
  4. 1. INTRODUCCIÓN
  5. 2. EFECTOS ADVERSOS CUTÁNEOMUCOSOS DE LAS TERAPIAS MOLECULARES DIRIGIDAS
  6. 3. TOXICIDADES CUTÁNEOMUCOSAS ASOCIADAS A INMUNOTERAPIA (CON INHIBIDORES DEL PUNTO DE CONTROL)
  7. 4. CONCLUSIONES
  8. 5. REFERENCIAS
  9. 6. GLOSARIO
  10. 7. ANEXO